Physician profile
Patrick J Mcdevitt
NPI 1245443860
$3,772.87
in general payments reported to CMS, 2019-2025
22 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $154 · 2021: $788 · 2022: $885 · 2023: $534 · 2024: $451 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,347.00 | 2019-2025 | |
| Janssen Biotech, INC. | $613.13 | 2019-2024 | Tremfya, Stelara |
| Gilead Sciences, INC. | $374.78 | 2019-2023 | |
| Pfizer INC. | $355.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $147.42 | 2021-2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.83 | 2019-2022 | |
| Daiichi Sankyo INC. | $95.14 | 2021-2023 | Injectafer |
| Celgene Corporation | $95.02 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $92.10 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $55.97 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $48.35 | 2022 | |
| Celltrion USA INC. | $43.72 | 2025 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $42.64 | 2021 | |
| Genzyme Corporation | $42.51 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $31.83 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.41 | 2023 | Onpattro |
| Nestle Healthcare Nutrition INC. | $25.00 | 2021-2022 | |
| Boston Scientific Corporation | $17.20 | 2024 | Cre Pro |
| Ferring Pharmaceuticals INC. | $16.13 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.49 | 2025 | Voquezna |
| Allergan, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcdevitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.